In a cardiovascular outcomes trial of liraglutide 1.8 mg, weight loss was sustained over a median trial period of 3.5 years in patients with type 2 diabetes who had either cardiovascular disease or risk factors for cardiovascular disease [60]
Teskey, G., Abrahem, R., Cao, R., Gyurjian, K., Islamoglu, H., Lucero, M., Martinez, A., Paredes, E., Salaiz, O., Robinson, B., & Venketaraman, V
Given as weekly injections, they act like a gut hormone known as GLP-1 that makes people feel fuller, helping them to lose weight
In that scenario, a defined cyclical course of the full GLOW blend has considerable validity, supported by studies looking at the synergy of the two latter peptides
What Is a Peptide Calculator and Why Do Researchers Need It